ABSTRACT
Goeckerman therapy for the treatment of psoriasis was first described in 1925 by Dr. William Goeckerman at the Mayo Clinic. Goeckerman therapy has long been considered the “gold standard” for psoriasis and is highly effective with a long duration of therapeutic effect. Goeckerman therapy was initially formulated for the treatment of psoriasis, but a modified version has been successfully used for the treatment of other skin conditions such as eczema. Goeckerman therapy is one of the oldest treatment modalities available for moderate to severe psoriasis. Goeckerman therapy has one of the longest reported average lengths of remission out of all the psoriasis treatments. Goeckerman therapy has an excellent side effect profile especially in comparison to other systemic therapies for psoriasis. The side effects of Goeckerman are minor and usually tolerable. Goeckerman therapy was initially performed as an inpatient treatment for days to weeks until the psoriasis cleared.
